Small Biopharmas Should Be Wary Of Early Results – US FDA Official
Two former Genzyme execs, one of whom now works at CDER, warn small companies to avoid over-emphasizing results from early, uncontrolled trials in their planning and business decision-making.
You may also be interested in...
One of the faces of FDA's effort to recruit senior leaders from outside its walls has decided to return to industry.
Drug industry executives discuss drug pricing and tax and regulatory reform in a high-profile meeting with President Trump at the White House.
OND Director Jenkins says Sarepta's Exondys 51 shouldn't be a model, gets an earful from patient advocates.